@article{2b698499e04849de8db8fb249b19276b,
title = "Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells",
abstract = "Our prior studies identified the prognostic significance of quantifying cPCs by multiparametric flow cytometry (MFC) in newly diagnosed multiple myeloma (NDMM) patients. We evaluated if a similar quantification of cPCs could add prognostic value to the current R-ISS classification of 556 consecutive NDMM patients seen at the Mayo Clinic, Rochester from 2009 to 2017. Those patients that had ≥5 cPCs/μL and either R-ISS stage I or stage II disease were re-classified as R-ISS IIB stage for the purposes of this study. The median time to next therapy (TTNT) and overall survival (OS) for patients with ≥5 cPCs/μL at diagnosis was as follows: R-ISS I (N = 110) - 40 months and not reached; R-ISS II (N = 69) - 30 and 72 months; R-ISS IIB (N = 96) - 21 and 45 months and R-ISS III (N = 281) - 20 and 47 months respectively. Finally, ≥ 5 cPCs/μL retained its adverse prognostic significance in a multivariable model for TTNT and OS. Hence, quantifying cPCs by MFC can potentially enhance the R-ISS classification of a subset of NDMM patients with stage I and II disease by identifying those patients with a worse than expected survival outcome.",
author = "Gonsalves, {Wilson I.} and Dragan Jevremovic and Bharat Nandakumar and Angela Dispenzieri and Buadi, {Francis K.} and David Dingli and Lacy, {Martha Q.} and Hayman, {Suzanne R.} and Prashant Kapoor and Nelson Leung and Amie Fonder and Miriam Hobbs and Hwa, {Yi Lisa} and Eli Muchtar and Rahma Warsame and Kourelis, {Taxiarchis V.} and Stephen Russell and Lust, {John A.} and Yi Lin and Go, {Ronald S.} and Siddiqui, {Mustaqeem A.} and Kyle, {Robert A.} and Gertz, {Morie A.} and Rajkumar, {S. Vincent} and Kumar, {Shaji K.}",
note = "Funding Information: Research reported in this publication was supported by Mayo Clinic Hematological Malignancies Program and in part by grants from the National Cancer Institute of the National Institutes of Health under Award Number K23CA218742 and P50CA186781. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Finally, this research is also supported in part by the Marion Schwartz Foundation for MM. Funding Information: Research reported in this publication was supported by Mayo Clinic Hematological Malignancies Program and in part by grants from the National Cancer Institute of the National Institutes of Health under Award Number K23CA218742 and P50CA186781. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Finally, this research is also supported in part by the Marion Schwartz Foundation for MM. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",
year = "2020",
month = mar,
day = "1",
doi = "10.1002/ajh.25709",
language = "English (US)",
volume = "95",
pages = "310--315",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",
}